Related Experiment Videos
Targeted Lung Cancer Treatments and Eye Metastasis
Paul Zarogoulidis1, Sofia Baka2, Sofia Labaki1
1Pulmonary Department-Oncology Unit, "G. Papanikolaou" General Hospital, Aristotle University of Thessaloniki, Thessaloniki, Greece.
Abstract:
Lung cancer remains the leading cause of death due to cancer. We do not have effective tools for the early detection of lung cancer, so patients are usually diagnosed at an advanced stage. However, novel therapies based on molecular pathways (such as those involving the epidermal growth factor receptor, anaplastic lymphoma kinase, serine/threonine-protein kinase B-Raf, proto-oncogene tyrosine-protein kinase ROS, c-Met proto-oncogene protein, and RET proto-oncogene protein) are now commonly used in the treatment of lung cancer. In particular, these therapies are considered as first-line treatments for non-small-cell lung cancer. This manuscript outlines previous research on these targeted treatments, focusing on whether they are effective against eye metastasis.
Insights
Targeted therapies show promise for non-small-cell lung cancer treatment. This review examines their effectiveness against lung cancer that has spread to the eyes.
Area of Science:
- Oncology
- Molecular Biology
- Ophthalmology
Background:
- Lung cancer is a leading cause of cancer death, often diagnosed late.
- Early detection methods for lung cancer are lacking.
- Novel molecularly targeted therapies are increasingly used for lung cancer treatment.
Purpose of the Study:
- To review targeted therapies for lung cancer.
- To assess the efficacy of these therapies against eye metastasis.
Main Methods:
- Literature review of targeted therapies.
- Analysis of studies on lung cancer treatments targeting specific molecular pathways.
- Focus on outcomes related to ocular metastasis.
Main Results:
- Targeted therapies, including those for epidermal growth factor receptor, anaplastic lymphoma kinase, serine/threonine-protein kinase B-Raf, ROS1, c-Met, and RET, are established first-line treatments for non-small-cell lung cancer.
- Research on the effectiveness of these targeted agents against eye metastasis is ongoing.
Conclusions:
- Targeted therapies represent a significant advancement in non-small-cell lung cancer management.
- Further investigation is required to fully understand and optimize the use of these therapies for treating lung cancer with eye metastasis.